Estudio de dosis con Propóleo en la enfermedad de Peyronie.
作者： Elizabeth Gonzalez Oramas , Rafaela Bordonado Ramirez , Manuel Lemourt Oliva , Félix Molina Castillo , Ada Rodriguez Barroso
DOI:
关键词:
摘要: OBJECTIVES: To determine the optimal dose for propoleum caps in Peyronie's disease. METHODS: We evaluated two groups of 17 patients each, analyzing pain and plaque size on physical ultrasound examination, before after treatment. Group A received with 300 mg powder daily six months, B 900 mg. RESULTS: Predominant ages were between 41 70 years. More than half group had pain; more did not have considering both there without pain. Physical reduction plaque: A: 0.6 cm, B: 0.8 cm. Ultrasound 1.3 In higher (B) clinical improvement started earlier. 79.4% treated preferred or slight improvement, being this result statistically significant. CONCLUSIONS: Pain is always an accompanying symptom Both doses administered reduced plaque, but one has earlier improvement. may consider way another treatment option disease, good results low cost.
unirioja.es
medes.com参考文章(14)
M. Brake, H. Loertzer, R. Horsch, H. Keller, Treatment of Peyronie's disease with local interferon‐α 2b BJUI. ,vol. 87, pp. 654- 657 ,(2001) , 10.1046/J.1464-410X.2001.02139.X
Kumaresan Ganabathi, Roger Dmochowski, Philippe E. Zimmern, Gary E. Leach, Peyronie's Disease: Surgical Treatment Based on Penile Rigidity Journal of Urology. ,vol. 153, pp. 662- 666 ,(1995) , 10.1016/S0022-5347(01)67679-1
U. Treiber, P. Gilbert, Surgical treatment of Peyronie's disease. Urologia Internationalis. ,vol. 47, pp. 240- 244 ,(1991) , 10.1159/000282229
A Kadioğlu, A Tefekli, T Köksal, M Usta, H Erol, Treatment of Peyronie's disease with oral colchicine: long‐term results and predictive parameters of successful outcome International Journal of Impotence Research. ,vol. 12, pp. 169- 175 ,(2000) , 10.1038/SJ.IJIR.3900519
Gerald Brock, Ates Kadioglu, Tom E Lue, None, Peyronie's disease: a modified treatment Urology. ,vol. 42, pp. 300- 304 ,(1993) , 10.1016/0090-4295(93)90619-L
Shahram S Gholami, Tom F Lue, None, Peyronie's disease. Urologic Clinics of North America. ,vol. 28, pp. 377- 390 ,(2001) , 10.1016/S0094-0143(05)70146-4
Athanasios Lamprakopoulos, Ioannis Zorzos, Michael Lykourinas, The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scandinavian Journal of Urology and Nephrology. ,vol. 34, pp. 355- 360 ,(2000) , 10.1080/003655900455422
Colombo F, Nicola M, [Peyronie's disease: ultrasonographic follow-up of ESWT]. Archivio italiano di urologia, andrologia. ,vol. 72, pp. 388- 391 ,(2000)
Spinelli M, Beretta G, Zanollo L, Zanollo A, Prosthetic implants for penile induration Archivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell'Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences. ,vol. 62, pp. 351- ,(1990)
E Massip, A Valls, J Bas, L González, A Romeu, E Buendía, M Corominas, M Mestre, Hypersensitivity reaction after orgotein (superoxide dismutase) administration. Allergologia Et Immunopathologia. ,vol. 18, pp. 297- 299 ,(1990)